Caroline M.P.W. Mandigers

3.1k total citations
24 papers, 1.1k citations indexed

About

Caroline M.P.W. Mandigers is a scholar working on Oncology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Caroline M.P.W. Mandigers has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Caroline M.P.W. Mandigers's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Caroline M.P.W. Mandigers is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Caroline M.P.W. Mandigers collaborates with scholars based in Netherlands, United States and Belgium. Caroline M.P.W. Mandigers's co-authors include John Raemaekers, Evelyn Tönnissen, Jules P.P. Meijerink, Federico Goodsaid, Louis van de Locht, Erik van Werkhoven, Jan H.M. Schellens, Marcel Soesan, Maarten J. Deenen and Annemieke Cats and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Caroline M.P.W. Mandigers

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caroline M.P.W. Mandigers Netherlands	13	688	318	284	168	163	24	1.1k
Ramya Ramaswami United States	22	722 1.0×	249 0.8×	222 0.8×	92 0.5×	328 2.0×	75	1.6k
Punita Lal India	21	374 0.5×	219 0.7×	241 0.8×	278 1.7×	100 0.6×	85	1.1k
Lorraine Pelosof United States	16	694 1.0×	224 0.7×	371 1.3×	299 1.8×	121 0.7×	35	1.8k
Xuan Bich Trinh Belgium	22	533 0.8×	380 1.2×	618 2.2×	184 1.1×	117 0.7×	39	1.4k
Roniel Cabrera United States	26	687 1.0×	399 1.3×	499 1.8×	255 1.5×	322 2.0×	73	3.0k
Alexandra M. Harrington United States	17	361 0.5×	208 0.7×	398 1.4×	67 0.4×	195 1.2×	64	1.0k
Gudrun Pohl Austria	19	579 0.8×	237 0.7×	661 2.3×	150 0.9×	158 1.0×	35	1.4k
M. Colombo Italy	23	413 0.6×	295 0.9×	321 1.1×	283 1.7×	342 2.1×	70	3.4k
Ritsu Yamamoto Japan	27	514 0.7×	163 0.5×	489 1.7×	167 1.0×	155 1.0×	68	2.4k

Countries citing papers authored by Caroline M.P.W. Mandigers

Since Specialization

Citations

This map shows the geographic impact of Caroline M.P.W. Mandigers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline M.P.W. Mandigers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline M.P.W. Mandigers more than expected).

Fields of papers citing papers by Caroline M.P.W. Mandigers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline M.P.W. Mandigers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline M.P.W. Mandigers. The network helps show where Caroline M.P.W. Mandigers may publish in the future.

Co-authorship network of co-authors of Caroline M.P.W. Mandigers

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline M.P.W. Mandigers. A scholar is included among the top collaborators of Caroline M.P.W. Mandigers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline M.P.W. Mandigers. Caroline M.P.W. Mandigers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Danielle, Joan B. Heijns, Caroline M.P.W. Mandigers, et al.. (2025). Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01). Clinical Cancer Research. 31(15). 3175–3181.

Fransen, Heidi P., Alexander de Graeff, Mathijs P. Hendriks, et al.. (2024). Relatives’ Unmet Needs in the Last Year of Life of Patients With Advanced Cancer: Results of a Dutch Prospective, Longitudinal Study (eQuiPe). Journal of Palliative Care. 40(1). 41–50. 1 indexed citations

Brom, Linda, Arnold Baars, Jean‐Paul van Basten, et al.. (2024). Open communication between patients and relatives about illness & death in advanced cancer—results of the eQuiPe Study. Supportive Care in Cancer. 32(4). 214–214. 3 indexed citations

Cohen, Daniëlle, Joan B. Heijns, Caroline M.P.W. Mandigers, et al.. (2023). Abstract P3-07-07: The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy in selected patients with early luminal breast cancer. Cancer Research. 83(5_Supplement). P3–7. 1 indexed citations

Raijmakers, Natasja, Arnold Baars, M.H.J. van den Beuken-van Everdingen, et al.. (2023). Trajectories of health‐related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study. Cancer. 130(4). 609–617. 18 indexed citations

Roij, Janneke van, Natasja Raijmakers, M.H.J. van den Beuken-van Everdingen, et al.. (2022). Quality of life and quality of care as experienced by patients with advanced cancer and their relatives: A multicentre observational cohort study (eQuiPe). European Journal of Cancer. 165. 125–135. 25 indexed citations

Berg, M. van den, Suzanne E. J. Kaal, D.D.M. Braat, et al.. (2022). Quality of integrated female oncofertility care is suboptimal: A patient‐reported measurement. Cancer Medicine. 12(3). 2691–2701. 4 indexed citations

Roij, Janneke van, Natasja Raijmakers, M.H.J. van den Beuken-van Everdingen, et al.. (2021). Experienced quality of care and emotional functioning of patients with advanced cancer and their relatives: Results of a multicenter observational cohort study (eQuiPe).. Journal of Clinical Oncology. 39(28_suppl). 3–3. 2 indexed citations

Voort, Anna van der, Mette S. van Ramshorst, Erik van Werkhoven, et al.. (2021). Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer. JAMA Oncology. 7(7). 978–978. 76 indexed citations

10.

Voort, Anna van der, Mette S. van Ramshorst, Erik van Werkhoven, et al.. (2020). Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.. Journal of Clinical Oncology. 38(15_suppl). 501–501. 24 indexed citations

11.

Ramshorst, Mette S. van, Anna van der Voort, Erik van Werkhoven, et al.. (2018). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 19(12). 1630–1640. 245 indexed citations

12.

Chamuleau, Martine E.D., Coreline N. Burggraaff, Marcel Nijland, et al.. (2018). MYC Rearrangement Positive Large B-Cell Lymphoma Patients Can Be Treated Successfully with R-CHOP Plus Lenalidomide: Results of a Multicentre Phase II HOVON Trial. SSRN Electronic Journal. 1 indexed citations

13.

Ramshorst, Mette S. van, Erik van Werkhoven, Ingrid A.M. Mandjes, et al.. (2017). A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03).. Journal of Clinical Oncology. 35(15_suppl). 507–507. 5 indexed citations

14.

Meulendijks, Didier, Linda M. Henricks, Bart Jacobs, et al.. (2017). Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. British Journal of Cancer. 116(11). 1415–1424. 81 indexed citations

15.

Heskamp, Sandra, Otto C. Boerman, Janneke D.M. Molkenboer‐Kuenen, et al.. (2015). Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients. PLoS ONE. 10(2). e0117745–e0117745. 29 indexed citations

16.

Ottevanger, Petronella B., et al.. (2015). Development and Evaluation of an Educational E-Tool to Help Patients With Non-Hodgkin's Lymphoma Manage Their Personal Care Pathway. SHILAP Revista de lepidopterología. 4(1). e6–e6. 7 indexed citations

17.

Aarts, Maureen J.B., Frank Peters, Caroline M.P.W. Mandigers, et al.. (2013). Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia. Journal of Clinical Oncology. 31(34). 4290–4296. 38 indexed citations

18.

Deenen, Maarten J., Annemieke Cats, Caroline M.P.W. Mandigers, et al.. (2012). [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].. PubMed. 156(48). A4934–A4934. 6 indexed citations

19.

Meijerink, Jules P.P., Caroline M.P.W. Mandigers, Louis van de Locht, et al.. (2001). A Novel Method to Compensate for Different Amplification Efficiencies between Patient DNA Samples in Quantitative Real-Time PCR. Journal of Molecular Diagnostics. 3(2). 55–61. 257 indexed citations

20.

Mandigers, Caroline M.P.W., Jules P.P. Meijerink, E. J. B. M. Mensink, et al.. (2001). Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood. 98(4). 940–944. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact